目的 探討通心絡(luò)膠囊聯(lián)合阿托伐他汀治療急性心肌梗死PCI術(shù)后炎性反應(yīng)的臨床研究。方法 2011年6月—2014年6月衡水市第二人民醫(yī)院收治的急性心肌梗死患者80例, 隨機分為對照組和治療組, 每組40例。對照組在基礎(chǔ)治療上口服阿托伐他汀鈣膠囊, 2粒/次, 1次/d。治療組在對照組基礎(chǔ)上加用通心絡(luò)膠囊, 4粒/次, 3次/d。兩組均連續(xù)用藥3個月。比較兩組患者治療前后氣虛血瘀癥狀和SAQ評分, 同時比較兩組C反應(yīng)蛋白(CRP)、腫瘤壞死因子-α(TNF-α)、細胞間黏附因子(ICAM-1)和白細胞介素-6(IL-6)、N末端B型利鈉肽原(NT-proBNP)水平。結(jié)果 治療后, 兩組患者氣虛血瘀癥狀評分較同組治療前顯著降低, SAQ評分顯著升高, 同組治療前后差異有統(tǒng)計學(xué)意義(P<0.05);且治療組氣虛血瘀癥狀和SAQ評分改善程度優(yōu)于對照組, 兩組比較差異有統(tǒng)計學(xué)意義(P<0.05)。治療后, 兩組患者的炎癥因子CRP、TNF-α、IL-6、ICAM-1和NT-proBNP均較治療前顯著降低, 同組治療前后差異有統(tǒng)計學(xué)意義(P<0.05);且治療后治療組各因子水平均低于對照組, 兩組比較差異有統(tǒng)計學(xué)意義(P<0.05)。結(jié)論 通心絡(luò)膠囊聯(lián)合阿托伐他汀治療急性心肌梗死PCI術(shù)后炎性反應(yīng)具有較好的臨床療效, 可改善患者臨床癥狀, 同時能夠降低患者術(shù)后炎癥因子水平, 具有臨床推廣價值。

Objective To explore the clinical study on Tongxinluo Capsules combined with atorvastatin in treatment of acute myocardial infarction with PCI postoperative inflammatory reaction. Methods The patients with acute myocardial infarction (80 cases) of the Second People's Hospital of Hengshui from June 2011 to June 2014 were randomly divided into treatment and control groups, and each group had 40 cases. The patients in the control group were po administered with Atorvastatin Calcium Capsules on the basis of conventional treatment, two capsules/time, once daily. The patients in the treatment group were po administered with Tongxinluo Capsules on the basis of the control group, four capsules/time, three times daily. The patients in two groups were treated for three months. Qixu Xueyu symptoms and SAQ scores before and after treatment in two groups were compared, while the levels of CRP, TNF-α, ICAM-1, IL-6, and NT-proBNP in two groups were compared. Results After treatment, Qixu Xueyu symptoms scores in two groups were significantly reduced, while SAQ scores in two groups increased significantly, and the difference was statistically significant in the same group before and after treatment (P < 0.05). After treatment, Qixu Xueyu symptoms and SAQ scores in the treatment group improved better than those in the control group, and there were differences between two groups (P< 0.05). After treatment, CRP, TNF-α, IL-6, ICAM-1, and NT-proBNP in two groups were significantly reduced, and the difference was significant in the same group before and after treatment (P < 0.05). After treatment, the levels of those inflammatory factors were lower than those in the control group, and there were differences between the two groups (P < 0.05). Conclusion Tongxinluo Capsules combined with atorvastatin has a good clinical effect on treatment of acute myocardial infarction with PCI postoperative inflammatory reaction, and can improve clinical symptoms, while can reduce the levels of inflammatory factors, which is worth clinical promotion.

河北省衡水市科學(xué)技術(shù)研究與發(fā)展指導(dǎo)計劃項目(11024Z)